Mounjaro Wegovy Menopause Obesity Treatment

After entering menopause, many people come in with the question, "I eat exactly the same as before, so why am I gaining weight like this?" Then they hear about Mounjaro and Wegovy and ask, "Which of the two is the better drug for menopausal women?" To put the conclusion first, you cannot declare which of the two is better. The two drugs differ in their mode of action, indications, and side-effect patterns, and in the menopausal period the background of even the same weight gain differs from person to person. In this article, rather than ranking the two drugs, I will lay out what should be considered together through the lens of a menopausal woman's body.

The starting point of menopausal weight change is the change in the hormonal environment that is the decrease in estrogen. When estrogen decreases, fat is redistributed from the hips and thighs toward the abdomen, visceral fat increases, and a tendency for insulin resistance to rise together is reported (Korean Society of Menopause materials, 2023). Even eating the same amount, the basal metabolic rate drops and muscle mass decreases, so the number on the scale moves poorly relative to one's effort.

In the clinic, many people blame themselves for this change as "I've become lazy." But this is closer to a result produced by hormones and metabolism than a problem of weak will. The hormonal background of menopausal weight gain was covered in more detail in the article organizing from a hormonal perspective why you gain weight more easily in menopause.

What matters is that menopausal abdominal obesity is not a simple matter of appearance but is intertwined with the risk of diabetes, hyperlipidemia, and cardiovascular disease. So when choosing a drug, you must look not only at "how many kilos come off" but also at "how to manage my metabolic risk together."

The most fundamental difference dividing the two drugs lies in which hormone signal they use. Wegovy (ingredient name semaglutide) acts on one receptor, GLP-1, while Mounjaro (ingredient name tirzepatide) acts simultaneously on two incretin receptors, GLP-1 and GIP. Because GIP additionally takes part in appetite, insulin secretion, and energy metabolism, it is explained that there is theoretically room for a greater extent of weight loss and blood sugar improvement.

In fact, a clinical trial directly comparing the two drugs (SURMOUNT-5, 2025) reported that with use over a certain period, the average extent of weight loss was greater for Mounjaro. Mounjaro also showed more favorable results in improving metabolic markers such as blood pressure, glycated hemoglobin, and triglycerides. However, this is a group average, and the result an individual actually obtains can have individual differences depending on starting weight, comorbidities, and diet and exercise habits.

If you are curious about the big principle by which GLP-1-class drugs reduce weight, looking together at the guide explaining how the GLP-1 diet injection works makes it easier to understand.

The two drugs differ in the texture of their approved indications. Wegovy is a drug approved for the purpose of weight management in obesity and overweight, while Mounjaro was originally developed and used as a type 2 diabetes treatment, and its obesity indication is handled by a separate formulation (Zepbound). In other words, even though they look like the same ingredient class, they differ at the starting point in "what is set as the main goal."

This difference is especially significant for menopausal women. It can be organized as follows.

• If you have no diabetes or it is mild and the main concern is weight and abdominal obesity, Wegovy can be one reasonable option.
• If diabetes or prediabetes is accompanied and improvement of blood sugar and metabolism is also needed, Mounjaro, which adds GIP action, can be a candidate for consideration.

However, this distinction is only a textbook big-picture framework; the actual prescription is decided after looking at blood tests and medical history. To comprehensively check menopausal metabolic health, I recommend first confirming what items are looked at in menopausal screening.

For both drugs, the most common side effects are gastrointestinal symptoms. Nausea, vomiting, diarrhea, and constipation are representative; they generally cluster in the early phase of raising the dose and tend to ease over time, as reported. Direct comparison data also report that the frequency of nausea and vomiting was somewhat lower for Mounjaro, but at high doses some people complain more often of constipation or stomach discomfort, so it is hard to say uniformly.

For menopausal women, one more thing must be looked after. During rapid weight loss, not only fat but also muscle and bone can decrease together. Menopause is already a time when bone density and muscle mass decrease, so management that combines protein intake and strength exercise while using the drug becomes more important. On menopausal bone and muscle management, you can refer to the article covering why managing bone density and muscle after menopause matters.

There are also common contraindications to be cautious of. It is known that careful judgment is needed in cases with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2), and in cases with a history of pancreatitis (U.S. FDA approval information, 2023). So confirmation of medical history and consultation must precede starting the drug.

Let me organize, in a table, the additional variables to consider when comparing the two drugs for menopausal women. It is not a table recommending one side, but a reference showing what should be weighed together.

Recent studies report that postmenopausal women can also obtain a degree of weight-loss effect similar to younger women (SURMOUNT analysis, 2025). Studies have also been published showing that when menopausal hormone therapy is combined, it may help with visceral fat reduction and metabolic improvement (Menopause journal, 2024). However, hormone therapy requires separate evaluation such as breast conditions and thrombosis risk, so whether to combine drugs must be decided through specialist consultation. In which cases menopausal hormone therapy is considered can be confirmed in the article covering when to start menopausal hormone therapy and how long to continue it.

In summary, there is no answer of "this drug no matter what" for menopausal women. Even the same weight gain has as variables whether diabetes is accompanied, cardiovascular risk, gastrointestinal sensitivity, bone density and muscle status, and even the possibility of combining hormone therapy. In my clinical experience, I often see that those who first draw their own metabolic risk map and then choose the drug that fits it are managed more stably, rather than vaguely choosing the drug with the greater average weight-loss extent.

If you are more curious about the general difference between Mounjaro and Wegovy itself, I recommend reading on with the article organizing the basic difference between Wegovy and Mounjaro, and if you want to narrow down to what Wegovy means for menopausal women, the article covering whether Wegovy's effects also help menopausal women.

With any drug, building a diet and exercise plan together with blood tests and medical-history confirmation before starting determines the result and safety. If you have menopausal weight and metabolism concerns, rather than deciding alone, start a consultation comfortably by chat. We will weigh it together and honestly guide you only on the tests that are truly necessary.

Written by: Lee Dong-hee Director · OB-GYN specialist · View doctor profile

First published August 15, 2025 · Last reviewed May 30, 2026

References: SURMOUNT-5 direct comparison trial (2025), SURMOUNT postmenopausal women analysis (2025), Menopause journal hormone therapy combination study (2024), U.S. FDA approval information (2023), Korean Society of Menopause materials (2023)

This article is intended to provide general health information and does not replace individual diagnosis or treatment. If you have symptoms, please consult through a medical visit.